BACKGROUND: Ovarian cancer commonly relapses after remission and new strategies to target microscopic residual diseases are required. One approach is to activate tumor-specific cytotoxic T cells with dendritic cells loaded with tumor cells. In order to enhance their immunogenicity, ovarian tumor cells (SK-OV-3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl). RESULTS: Treatment for 1 h with 60 microM HOCl was found to induce necrosis in all SK-OV-3 cells. Oxidized, but not live, SK-OV-3 was rapidly taken up by monocyte-derived dendritic cells, and induced partial dendritic cell maturation. Dendritic cells cultured from HLA-A2 healthy volunteers were loaded with oxidized SK-OV-3 (HLA-A2-) and co-cultured with autologous T cells. Responding T cells were tested for specificity after a further round of antigen stimulation. In ELISPOT assays, T cells produced interferon-gamma (IFN-gamma) in response to the immunizing cellular antigen, and also to peptides coding for MUC-1 and HER-2/neu HLA-A2 restricted epitopes, demonstrating efficient cross-presentation of cell-associated antigens. In contrast, no responses were seen after priming with heat-killed or HCl-killed SK-OV-3, indicating that HOCl oxidation and not cell death/necrosis per se enhanced the immunogenicity of SK-OV-3. Finally, T cells stimulated with oxidized SK-OV-3 showed no cross-reaction to oxidized melanoma cells, nor vice versa, demonstrating that the response was tumor-type specific. CONCLUSIONS: Immunization with oxidized ovarian tumor cell lines may represent an improved therapeutic strategy to stimulate a polyclonal anti-tumor cellular immune response and hence extend remission in ovarian cancer.
BACKGROUND:Ovarian cancer commonly relapses after remission and new strategies to target microscopic residual diseases are required. One approach is to activate tumor-specific cytotoxic T cells with dendritic cells loaded with tumor cells. In order to enhance their immunogenicity, ovarian tumor cells (SK-OV-3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl). RESULTS: Treatment for 1 h with 60 microM HOCl was found to induce necrosis in all SK-OV-3 cells. Oxidized, but not live, SK-OV-3 was rapidly taken up by monocyte-derived dendritic cells, and induced partial dendritic cell maturation. Dendritic cells cultured from HLA-A2 healthy volunteers were loaded with oxidized SK-OV-3 (HLA-A2-) and co-cultured with autologous T cells. Responding T cells were tested for specificity after a further round of antigen stimulation. In ELISPOT assays, T cells produced interferon-gamma (IFN-gamma) in response to the immunizing cellular antigen, and also to peptides coding for MUC-1 and HER-2/neu HLA-A2 restricted epitopes, demonstrating efficient cross-presentation of cell-associated antigens. In contrast, no responses were seen after priming with heat-killed or HCl-killed SK-OV-3, indicating that HOCl oxidation and not cell death/necrosis per se enhanced the immunogenicity of SK-OV-3. Finally, T cells stimulated with oxidized SK-OV-3 showed no cross-reaction to oxidized melanoma cells, nor vice versa, demonstrating that the response was tumor-type specific. CONCLUSIONS: Immunization with oxidized ovarian tumor cell lines may represent an improved therapeutic strategy to stimulate a polyclonal anti-tumor cellular immune response and hence extend remission in ovarian cancer.
Authors: Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos Journal: Clin Cancer Res Date: 2013-07-09 Impact factor: 12.531
Authors: Cheryl Lai-Lai Chiang; Andrea R Hagemann; Rachel Leskowitz; Rosemarie Mick; Thomas Garrabrant; Brian J Czerniecki; Lana E Kandalaft; Daniel J Powell; George Coukos Journal: PLoS One Date: 2011-12-14 Impact factor: 3.240
Authors: Cheryl L-L Chiang; Dawn A Maier; Lana E Kandalaft; Andrea L Brennan; Evripidis Lanitis; Qunrui Ye; Bruce L Levine; Brian J Czerniecki; Daniel J Powell; George Coukos Journal: J Transl Med Date: 2011-11-14 Impact factor: 5.531
Authors: Jiří Pokorný; Alberto Foletti; Jitka Kobilková; Anna Jandová; Jan Vrba; Jan Vrba; Martina Nedbalová; Aleš Čoček; Andrea Danani; Jack A Tuszyński Journal: ScientificWorldJournal Date: 2013-06-11
Authors: Iart Luca Shytaj; Barbara Chirullo; Wendeline Wagner; Maria G Ferrari; Rossella Sgarbanti; Alessandro Della Corte; Celia LaBranche; Lucia Lopalco; Anna Teresa Palamara; David Montefiori; Mark G Lewis; Enrico Garaci; Andrea Savarino Journal: Retrovirology Date: 2013-07-16 Impact factor: 4.602